Brandenburg Kapital - News about Seqstant GmbH

Potsdam, March 2024 – The Teltow-based company has developed a SaaS solution that makes it possible to detect pathogens quickly and comprehensively with one click using sequencing. With the analysis software 'LiveGene', pathogens can be fully identified from various types of patient samples in order to treat patients with serious infections earlier and in a more targeted manner.

Since March 2024, this analyzing software is now CE-approved (according to IVDR standard) and commercially available for pathogen-diagnostic.

By this, the company has achieved an important milestone and has proven its dedication to deliver peak performance in the healthcare sector with quality and innovation. The healthcare system has now access to a faster and more comprehensive analytic for pathogens, simply with the press of a button. This way hospitals are enabled to gain insight into the pathogens of their patients in less than 48 hours, which is a big leap for patient care.Brandenburg Kapital ist invested in Seqstant since 2023.

Click here for the complete article: https://seqstant.com/de/#seqstant

About Seqstant GmbH

Seqstant is an innovative company dedicated to improving pathogen diagnostics. Founded in 2021 at the Hasso Plattner Institute, Seqstant has already received ISO13485 certification in 2022. With their product, they are improving medical diagnostics and thus contributing to improved patient care.

For more information, please visit : www.brandenburg-kapital.de; https://seqstant.com